EU Regulators Back Roche's Obinutuzumab for Lupus, Opening a New Indication Beyond Oncology

Roche has cleared a significant European regulatory step for obinutuzumab, sold as Gazyvaro in the EU, in systemic lupus erythematosus (SLE). The company said on 13 November 2026 that the EMA's human medicines committee, the CHMP, had issued a positive opinion for the antibody in this autoimmune disease.

The recommendation applies to adults with moderate-to-severe, active, autoantibody-positive SLE whose disease persists despite standard treatment. Obinutuzumab would be used on top of that existing therapy rather than in place of it. The facts provided do not include any sales forecasts, pricing plans or launch timing, so the commercial size of the opportunity cannot be assessed from this announcement alone.

The opinion draws on the phase III ALLEGORY study. At week 52, 76.7% of patients given obinutuzumab met the SRI-4 response criterion, against 53.5% of those given placebo. Roche reports that the trial surfaced no new safety signals.

The next milestone is a European Commission decision, which Roche expects soon. As general context, the Commission usually follows a CHMP opinion when it grants a marketing authorisation or an extension of indication. Roche also said the US Food and Drug Administration has accepted a supplemental Biologics License Application for the same use, so decisions on both sides of the Atlantic are now in progress.